When "no data" is the complete and final answer posts 91–120
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
It is the kind of thing that is obvious once and never again.
Understood. Thank you for being specific about the limits of it.
Narrowing post #91, because the general version has more than one answer.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Old habit: I write down the expected answer before I calculate it.
Where I part company with post #91, and it is a narrow parting.
Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.
The short version is the first sentence; the rest is why.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Posted with less confidence than the sentence structure implies.
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
That distinction has done more work for me than anything else in this category.
Quietly grateful for the plain phrasing. Not every thread gets that.
This follows post #99 rather than contradicting it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I would hold that lightly until someone with a larger sample weighs in.
I read post #99 twice before replying, because I had assumed the opposite.
On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Collapsed as off-topic by two members at trust level 3 or above
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
Reading it back, the second half matters more than the first.
Everything in post #103 holds. The case it does not cover is the one I have.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
If the premise is wrong, everything after it is decoration.
Narrowing post #107, because the general version has more than one answer.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Correct me on the arithmetic if it is wrong; I would rather know.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Adding the measurement that post #110 says would settle it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That holds for the case as described. Change the assumptions and it may not.
Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.
That is the version I use. It may not be the version that is correct.
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The honest answer is that it depends, and here is what it depends on.
Collapsed as off-topic by two members at trust level 3 or above
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Same experience here, different supplier, so it is at least not unique to one of them.
For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.